Skip to content

When China accepts clinical trial data from abroad

Oak
Two sealed laboratory vessels, one blue and one amber, joined by a slender glass bridge carrying a thread of light.

China accepts clinical trial data produced abroad in support of a drug registration, and it accepts the data in full, in part or not at all.1 The outcome turns on the quality of the data and on whether ethnic factors affect the drug’s efficacy or safety. Where the data is accepted in part, the applicant runs further trials aimed at the uncertainty, after discussion with the Center for Drug Evaluation.1

A reader who knows the EU approach looks first at whether the foreign trial met good clinical practice. The Chinese guidance asks that question and then a second one, which is whether the results can be extended to the Chinese population. Compliance with good clinical practice settles the first question only.

The guidance and its scope

The National Medical Products Administration issued the Technical Guidance on Accepting Overseas Clinical Trial Data for Drugs on 10 July 2018, as Announcement No. 52 of 2018.1 It applies where an applicant for registration in China relies on clinical trial data obtained abroad as clinical evaluation material.1

The data covered includes data that an applicant obtains abroad through simultaneous development of an innovative drug inside and outside China. Bioequivalence data from generic drug development abroad may also be used, where it is complete and can be evaluated.1

Basic principles

The applicant must ensure that the overseas data is true, complete, accurate and traceable.1 The process that produced the data must meet the good clinical practice requirements of the International Council for Harmonisation.1 The applicant must also ensure that the trial design is scientific, that the quality management system for the trial meets requirements, and that the statistical analysis is accurate and complete.1

For a drug that is developed simultaneously inside and outside China and will be tried in China, the applicant may consult the Center for Drug Evaluation before it carries out the pivotal trial. The purpose is to make sure the design of that trial meets the basic technical requirements for registration in China.1

Completeness

An applicant that relies on overseas trials must provide all the overseas clinical trial data. Selective submission is prohibited, and completeness is a basic condition for acceptance of the application.1

Three situations are addressed.1

  • Early trials were run abroad and later development takes place in China. The applicant evaluates the early data, and complete data may support the later trials after discussion with the Center.
  • All trials were completed abroad and the drug is not yet on the market. The applicant provides the complete overseas data package.
  • The drug is already on the market abroad. The applicant also provides updated safety and efficacy data.

What the submission contains

Where development runs inside and outside China at the same time, the applicant assembles every trial into one complete data package under the registration measures.1 The material covers biopharmaceutics, clinical pharmacology, efficacy and safety. The guidance encourages submission in the common technical document format.1

Each kind of data has its own task.1

  • Biopharmaceutic data gives the key results on bioavailability and bioequivalence.
  • Clinical pharmacology data covers pharmacokinetics and pharmacodynamics, with an analysis of ethnic sensitivity by region and by ethnicity.
  • Efficacy data includes the pivotal overseas trials and the trials run in China. It must confirm efficacy overall and analyse the consistency of the Chinese subgroup with the overall population.
  • Safety data includes all data used for safety evaluation inside and outside China, analysed overall and for the consistency of the Chinese subgroup.

The guidance follows the principles of ICH E5 on ethnic factors in the acceptance of foreign clinical data. The analysis of the Chinese subgroup against the overall population supports the extension of overseas results to the Chinese population.1

The three outcomes

Full acceptance. The overseas data is true and reliable and meets good clinical practice and the requirements of registration inspection. It supports the evaluation of efficacy and safety for the target indication. No ethnically sensitive factor affects efficacy or safety.1

Partial acceptance. The data meets the first two conditions, and an ethnically sensitive factor affects efficacy, safety or both. Extension of the data to the Chinese population carries considerable uncertainty. The applicant analyses the factors, discusses them with the Center for Drug Evaluation and then runs clinical trials aimed at them.1

No acceptance. The data has major problems of truthfulness, completeness, accuracy or traceability, and cannot adequately support the evaluation of efficacy and safety for the target indication. The applicant follows the approach for an innovative drug and runs a systematic clinical programme in China.1

Conditional acceptance

A further route exists for drugs for critical illness, for rare disease and for children, where effective treatment is lacking. Where the overseas data for such a drug falls under partial acceptance, it may be accepted on conditions. Further efficacy and safety data is then collected after the drug is on the market.1

The Drug Administration Law provides separately for conditional approval. A drug for a seriously life-threatening disease with no effective treatment, or a drug urgently needed for public health, may be approved on conditions where trial data already shows efficacy and can predict clinical value. The conditions are recorded in the registration certificate.2

Questions people also ask

Does China accept clinical trial data from other countries?

The 2018 guidance provides for overseas clinical trial data to be accepted in full, in part or not at all, according to the quality of the data and the effect of ethnic factors.1

Is a trial in Chinese subjects always required?

Full acceptance is available where no ethnically sensitive factor affects efficacy or safety.1 Partial acceptance leads to trials in China aimed at the factors identified.1

Can an applicant submit only its successful overseas trials?

The applicant must provide all overseas clinical trial data, and selective submission is prohibited.1

Can bioequivalence data from abroad support a generic drug in China?

Bioequivalence data from generic drug development abroad may be used for a registration application where it is complete and can be evaluated.1

Footnotes

  1. National Medical Products Administration, Technical Guidance on Accepting Overseas Clinical Trial Data for Drugs, Announcement No. 52 of 2018. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24

  2. Drug Administration Law of the People’s Republic of China (revised 2019), Article 26. http://www.gd.gov.cn/zwgk/wjk/zcfgk/content/post_2521598.html ↩

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.